- Home
- BCG vs CRIS Comparison
BCG vs CRIS Comparison
Compare BCG & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCG | CRIS |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 20.6M |
| IPO Year | 2025 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BCG | CRIS |
|---|---|---|
| Price | $1.56 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 45.6K | ★ 212.7K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.50 | 91.57 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $187,144,000.00 | $9,898,000.00 |
| Revenue This Year | N/A | $27.10 |
| Revenue Next Year | N/A | $67.74 |
| P/E Ratio | $17.22 | ★ N/A |
| Revenue Growth | 10.80 | ★ 31.50 |
| 52 Week Low | $1.26 | $0.18 |
| 52 Week High | $3.44 | $6.74 |
Technical Indicators
Market Signals| Indicator | BCG | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 57.94 | 30.00 |
| Support Level | $1.43 | $0.66 |
| Resistance Level | $1.61 | $5.55 |
| Average True Range (ATR) | 0.10 | 0.54 |
| MACD | 0.02 | -0.48 |
| Stochastic Oscillator | 75.00 | 7.27 |
Price Performance
Historical ComparisonAbout BCG Binah Capital Group Inc.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.